NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

Key Terms

electronic health record technical

A digital version of a patient’s medical chart that collects health information — diagnoses, medications, lab results, imaging and doctors’ notes — in one place so authorized clinicians can view and update it. For investors, electronic health records matter because they drive revenue and costs for companies that build, sell or rely on them, influence how quickly care is delivered, and create opportunities (and risks) tied to data access, software updates, regulation and patient privacy. Think of it as an online file cabinet for health that affects how the healthcare system runs and spends money.

ehr technical

EHR stands for electronic health record, a digital version of a patient’s complete medical file that replaces paper charts and collects diagnoses, medications, test results and treatment history in one place. For investors, EHR systems matter because they drive recurring revenue for software and services, affect healthcare providers’ costs and efficiency, and create data assets and integration opportunities that can influence a company’s growth and regulatory risk.

liquid biopsy medical

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

molecular residual disease medical

Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these measurements can predict relapse, guide whether additional therapy is needed, and shape the market for diagnostics and drugs—much like finding embers after a fire helps decide if more firefighting is required.

mrd medical

MRD stands for minimal residual disease, the tiny number of cancer cells that can remain in the body after treatment and that may not show up on routine scans. Detecting MRD is like finding a few seeds left in a garden after clearing: it helps doctors predict the chance of relapse and measure how effective a therapy is, which investors watch because MRD results can influence clinical trial success, regulatory decisions, and a drug’s market potential.

precision oncology medical

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that its oncology testing portfolio is now available through Epic Aura, enabling seamless access to oncologists and health systems across the United States through the Epic electronic health record (EHR) workflow.

Through this integration, physicians can order NeoGenomics’ comprehensive suite of tests, spanning solid tumors and hematologic malignancies, and view results in the same system they use to manage patient care. This streamlined approach lowers barriers to entry for hospitals and health systems, enhances the scalability of NeoGenomics’ testing capabilities, and could drive 20-30% increase¹ in test adoption per site, supporting faster time to treatment for patients facing a cancer diagnosis.

“Clinicians need timely access to the right diagnostics within the systems they already rely on,” said Tony Zook, Chief Executive Officer of NeoGenomics. “Successfully integrating with Epic enables us to bring our testing capabilities directly into everyday care delivery, with the potential to help patients begin appropriate therapy sooner while allowing health systems to scale precision oncology more efficiently.”

This integration represents a significant step forward in NeoGenomics’ digital health strategy, strengthening connectivity across community oncology practices and large health systems. This scalable, “build once, deploy broadly” infrastructure will support the delivery of next-generation diagnostic capabilities, including liquid biopsy and molecular residual disease (MRD).

About NeoGenomics

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Epic Aura integration, including the potential to streamline test ordering, accelerate clinical decisions, drive adoption of precision oncology, increase test adoption per site and support faster time to treatment, as well as the Company's Digital Health strategy and the anticipated delivery of next-generation diagnostic capabilities. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks related to the Company’s ability to successfully implement and maintain the Epic Aura integration, the willingness of health systems and physicians to adopt the integrated ordering workflow, the Company’s ability to achieve projected increases in test adoption, the timing and success of the Company’s Digital Health strategy, general market conditions, competitive dynamics and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Reference

1. Huelsman K, Vasiliadis L, Liette A, Wernke K, Parchman A, Maher J, Rice C. Integrating discrete genomic data with an EHR improves patient care, provider satisfaction, and program metrics. Association of Cancer Care Centers. 2024;39(2):12-24. Accessed April 21, 2026. https://cdn.sanity.io/files/0vv8moc6/accc-cancer/b351ee63a2f4679660f6e409dd3564c61d15e212.pdf

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423070414/en/

Investor Contact
InvestorRelations@neogenomics.com

Media Contact
Andrea Sampson
asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.